Broadcast of "Contemporary Issues in Transplantation: Delayed Graft Function -- Clinical Implications and Case Management", a Satellite Symposium presented during the 33rd Annual Scientific Meeting of the American Society of Nephrology, October 12, 2000 in Toronto, Ontario, Canada

This program was provided by the Institute for Continuing Healthcare Education (ICHE). This was an approved ASN satellite symposium. It was not part of the official 33rd Annual Meeting as planned by the ASN Program Committee.

To access these talks at no charge you need to first REGISTER WITH HDCN at this link.





Program Overview

Delayed graft function (DGF) is the most common complication of the immediate postoperative period in renal transplantation and affects up to 50% of the cadaveric renal transplants in the United States. Although the incidence and definition of DGF vary among transplant centers, the consequences are uniform: prolonged hospital stay, additional invasive procedures, and additional cost to the patient and health-care system. This symposium will address the incidence, clinical implications, and pathophysiology of DGF as well as its pharmacoeconomic impact. In addition, a clinical review of methods for prevention and treatment of DGF will be discussed. The symposium is designed to include both the surgical and the nephrology views on DGF and will conclude with a panel discussion by the faculty.

Program Objectives
At the conclusion of this activity, participants should be able to do the following:
  • Describe the incidence and clinical implications of delayed graft function in renal transplantation.
  • Summarize the impact of delayed graft function in renal transplantation on graft survival and on additional costs to the patient and health-care system.
  • Discuss in detail the pathophysiology of delayed graft function in renal transplantation.
  • Discuss current medical efforts to prevent and treat delayed graft function in renal transplantation from the perspective of both the surgeon and nephrologist.

Target Audience

This program has been designed to meet the educational needs of renal transplant surgeons and nephrologists with an interest in transplant-related topics.

Accreditation
Contemporary Issues in Transplantation-Delayed Graft Function: Clinical Implications and Case Management was developed by the Institute for Continuing Healthcare Education. The Institute of Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Program participants at the symposium received up to 3 hours of Category 1 CME credit toward the AMA Physician's Recognition Award. The Institute of Healthcare Education has approved this web broadcast of the symposium for information only. The web broadcast is not approved for continuing education credit.

Commercial support
This activity was supported by an educational grant from SangStat. The Institute for Continuing Healthcare Education recognizes and adheres to the ACCME Standards for Commercial Support of Continuing Medical Education.




Welcome and Introduction
Kenneth L. Brayman, MD, PhD, Cochair
Introduction to Delayed Graft Function
Arthur J. Matas, MD
Delayed Graft Function and Kidney Allocation
Francis L. Delmonico, MD
Prevention and Treatment of Delayed Graft Function
Roy D. Bloom, MD, Cochair.
Panel Discussion
Faculty



Bloom

Brayman

Delmonico

Matas
Roy D. Bloom, MD, Cochair. Assistant Professor of Medicine, Comedical Director, Kidney/Pancreas Transplant Program, University of Pennsylvania, Philadelphia, PA.  (more)

Kenneth L. Brayman, MD, PhD, Cochair. Associate Professor of Surgery, University of Pennsylvania, Philadelphia, PA.  (more)

Francis L. Delmonico, MD. Professor of Surgery, Harvard Medical School, Director of Renal Transplantation, Massachusetts General Hospital, Medical Director, New England Organ Bank, Boston, MA.  (more)

Arthur J. Matas, MD. Professor of Surgery, Director of Renal Transplantation, Fairview University Medical Center, Minneapolis, MN.  (more)

Dr. Bloom has received honoraria related to the development of educational materials from SangStat. He has also received honoraria related to speakers' bureau activities from SangStat.

Dr. Bloom has indicated that he will include the discussion of anti-thymocyte globulin (rabbit) for intra-operative administration to prevent delayed graft function. Anti-thymocyte globulin (rabbit) has not been approved by the FDA for this use in the United States. Dr. Bloom has indicated that he will not include the discussion of products that have not been approved by the FDA for any use.

Dr. Brayman has received honoraria related to speakers' bureau activities from SangStat. Wyeth-Ayerst Laboratories, and Novartis Pharmaceuticals Corporation. He has also received grant support related to research activities from Novartis Pharmaceuticals Corporation, Wyeth-Ayerst Laboratories, and Fujisawa Pharmaceutical Co.

Dr. Brayman has indicated that he will include the discussion of anti-thymocyte globulin (rabbit) for intra-operative administration to prevent delayed graft function. Anti-thymocyte globulin (rabbit) has not been approved by the FDA for this use in the United States. Dr. Brayman has indicated that he will not include the discussion of products that have not been approved by the FDA for any use.

Dr. Delmonico has received honoraria related to formal advisory activities from Genzyme Data Safety Monitoring Board.Dr. Matas has received honoraria related to formal advisory activities from Novartis Pharmaceuticals Corporation. He has also received honoraria related to the development of educational materials from SangStat.

Dr. Delmonico has indicated that his presentation will not include the discussion of unlabeled uses of commercial products or products that have not yet been approved by the FDA for use in the United States for any purpose.

Dr. Matas has received grant support related to research activities from Roche Pharmaceuticals, Novartis Pharmaceuticals Corporation, Fujisawa Pharmaceutical Co., Wyeth-Ayerst Laboratories, and SangStat.

Dr. Matas has indicated that his presentation will not include the discussion of unlabeled uses of commercial products or products that have not yet been approved by the FDA for use in the United States for any purpose.


This was not part of the official 33rd Annual Meeting as planned by the ASN Program Committee. Supported by an unrestricted educational grant from SangStat.

The opinions expressed in this publication are those of the participating faculty and not those of the Institute for Continuing Healthcare Education, SangStat, or any manufacturers of products mentioned herein.

This educational activity may include the discussion of products for indications not approved by the FDA. Disclosures of off-label discussions are found in the faculty section.

Participants are encouraged to consult the package inserts for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important with new or infrequently used products.

Copyright © 2001, Institute for Continuing Healthcare Education (the Institute), a division of CoMed Communications, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining written permission from the Institute.
 
HDCN HOME